Case Series: Efficacy and Safety of Hemoadsorption With HA-330 Adsorber in Septic Pediatric Patients With Cancer.

Background: Sepsis is a frequent cause of death in hospitalized patients and, in detail, in neonatal, pediatric, and adult intensive care units (ICUs). Severe sepsis has a very poor prognosis. Indeed, the mortality rate varies between 30 and 70% during the first 7-14 days. Despite a timely and appropriate therapy, the prognosis of severe sepsis is too often negative. Therefore, new therapeutic resources are under investigation in order to further improve prognosis. Case series: Here, we reported three septic children in whom we used extracorporeal blood purification therapy with hemoadsorption device HA330 (Jafron Biomedical Co., Ltd., China), aiming to scavenge and eliminate bacterial toxins and inflammatory mediators from the blood. Discussion and Conclusion: This small case series first showed that hemoperfusion with HA330 cartridge may be an effective and relatively safe adjunctive treatment to counterbalance the cytokine storm in septic children with hematological disorders. Further studies are needed to confirm and further support its safety and efficacy in a large number of pediatric patients.

Role of Yes-associated protein in cancer: An update.

Yes-associated protein (YAP) is an oncoprotein located in the cytoplasm in an inactive form, and when activated, it translocates to the nucleus and activates the transcription of genes responsible for cell division and apoptosis. YAP is one of the downstream regulatory proteins in the Hippo signaling pathway, which is important in cell proliferation and regeneration. Due to its great importance, YAP is regulated very strictly by different regulatory systems. The present review will focus on the canonical pathways of YAP, and will provide details on the most recent findings regarding its regulation and role in tumorigenesis, specifically in prostate tumor progression.